Ipamorelin: a beginner's guide to the growth hormone peptide

Key takeaways

• Ipamorelin is a lab-made pentapeptide, a chain of five amino acids, that signals the pituitary to put out a short pulse of the body's own growth hormone. It has no approved medical use and no drug label .
• The human evidence is thin and old. The core data are two small, short-term studies: an early trial in healthy men confirmed it triggers a growth-hormone release, and the founding paper showed it does so without much of a cortisol bump . No human trial backs the sleep, recovery, or muscle claims people take it for.
• It is usually paired with CJC-1295, a longer-acting peptide that works through a different receptor and keeps growth hormone and IGF-1 raised for days . That pairing rests on mechanism reasoning, not on any trial of the combination itself .
• It is not FDA-approved. On October 29, 2024 an FDA advisory committee voted against clearing ipamorelin for pharmacy compounding, 12 to 0, citing a lack of safety and efficacy data .
• It is banned for tested athletes at all times, in and out of competition, and named directly on the WADA prohibited list as a growth hormone secretagogue .

The short version: plausible mechanism, thin human proof

Ipamorelin is a synthetic peptide, a short chain of five amino acids . It belongs to a class called growth hormone secretagogues: peptides that tell the pituitary gland to release a short burst of the growth hormone your body already makes, instead of adding hormone from outside. It is sold as a research chemical, not a medicine.

People take it as a small injection under the skin, usually from a freeze-dried vial they mix with liquid first. Whichever way you look at it, the starting point is the same: an unapproved compound with a thin human evidence base and a lot of community confidence.

What people actually use it for

In peptide and gym circles, ipamorelin has a reputation as the cleaner growth-hormone option. People reach for it hoping for better sleep, faster recovery, and a bit more lean muscle, and they like that it is described as skipping the extra hunger and stress-hormone spike linked to older peptides in its class . Pre-bed dosing is popular; the idea is to line the dose up with the body's own overnight growth-hormone release.

Almost all of that is anecdote. These are user reports and community habits, not results from controlled human trials, and the effects people describe tend to be subtle and slow rather than dramatic. Of the reasons people give, only the lower-cortisol point has any primary-literature basis, and even that comes from early studies, not long-term human trials .

What the science actually shows

The human case is small and dated. In the one healthy-volunteer study, ipamorelin produced a dose-dependent growth-hormone release, but it was tiny: about eight healthy men at each of five infusion rates, given intravenously in a single session . The founding paper that named it the first selective growth hormone secretagogue is mostly animal and cell work, plus the finding that it released growth hormone without a meaningful cortisol rise .

That is close to the whole human evidence base. The FDA reviewed ipamorelin and concluded its effectiveness is limited, with no data supporting the under-the-skin route people actually use . The sleep, recovery, and muscle goals people take it for were never the target of a trial, and long-term safety data are essentially absent.

The catch: unapproved, unregulated, and banned in sport

• Not approved, and turned down for compounding. There is no FDA-approved ipamorelin, no USP or NF monograph, and it is not part of any approved drug . On October 29, 2024 an FDA advisory committee voted 12 to 0 against adding it to the list of substances pharmacies may compound with, citing a lack of safety and efficacy data .
• Banned in sport. Growth hormone secretagogues are prohibited at all times under the WADA list, which USADA enforces, and ipamorelin is named on it directly, as is CJC-1295 . Because it is not an approved medicine, a tested athlete has no approved therapeutic use to base an exemption on.
• Blood sugar runs the wrong way. Ipamorelin pushes growth hormone up, and the FDA said it could not rule out the same risks seen with approved growth-hormone-raising drugs, including glucose intolerance and diabetes. That is high blood sugar, not low .
• The one controlled trial was a hard setting. The only controlled ipamorelin outcome study was intravenous, in sick post-surgical patients, and the reported side effects there included low potassium, insomnia, high blood sugar, nausea, vomiting, abdominal bloating, and two deaths whose link to the drug was unclear . That is very different from a small pre-bed injection, so do not read those as expected effects of community-dose use, but do not assume the drug has a clean human record either.
• What is in the vial is not checked. Because ipamorelin is unapproved, nobody verifies what a research-chemical vial actually contains. The FDA found key quality data missing, with no certificates of analysis, and flagged that peptides like this can trigger an immune reaction . So the amount and purity can vary, and measuring mistakes are easy to make.
• Side effects people report: transient hunger, a mild headache, flushing, or tingling at the injection site are the common ones. Stop and see a clinician for persistent joint pain, swelling, vision changes, or blood-sugar changes.

How people take it, and where the real numbers live

If you are going to use it, the goal is to do it as safely as the unknowns allow. Ipamorelin ships as a freeze-dried powder you mix with bacteriostatic water before drawing a dose, and people inject it under the skin. Pre-bed timing is the popular slot, timed to line up with the body's own overnight growth-hormone release.

None of the handling matters if the vial does not actually contain what the label says, and the research-chemical channel rarely comes with independent testing. What is really in the vial is the assumption every other decision rests on, which is why the purity point above matters.

Where to read more

This guide is the on-ramp. When you want the full picture, CJC-1295 and ipamorelin vs pharmaceutical HGH weighs the peptide-stack approach against actual prescription growth hormone. Sleep architecture and recovery covers how deep sleep and growth-hormone release connect, which is the logic behind the pre-bed timing. Injected peptides and natural production covers whether nudging your own hormones has a downside, and spotting high-quality peptides helps with the vial-quality problem. The ipamorelin library entry is the quick reference for dosing ranges, storage, and sources.

How we sourced this, and the fine print

Every claim on this page is pinned to a published source: the early human and animal pharmacology, the CJC-1295 data, the FDA compounding record, and the WADA anti-doping list. Where nobody has tested it in people yet, this guide says so rather than guessing.

For research and educational purposes only. Not medical advice.

pepSmart has not commissioned independent clinical review of this article.

More on how we write and source these guides: Editorial process and contributor disclosure and Sourcing posture.

Spot an error? Email corrections via /about.

Sources: 8 entries, all primary or authoritative government sources (PubMed, the FDA, USADA, and the WADA prohibited list), last reviewed 2026-07-13.

Related tools

• Protocol builder overview - Public overview of the Pro protocol builder.
• Peptide reconstitution calculator - Convert vial mass and BAC water volume into mcg/ml.
• BAC water calculator - Solve BAC water volume for a target concentration.
• Multi-dose vial calculator - Estimate doses per vial and a projected vial-empty date.
• Reconstituted-vial storage window calculator - Estimate a generic usable-window date and days remaining.
• Peptide half-life calculator - Estimate single-dose decay from cited half-life constants.